Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
43.76 USD | +1.41% | +6.99% | +18.28% |
07/05 | Halozyme Therapeutics Q1 Non-GAAP Earnings, Revenue Rise; 2024 Guidance Reaffirmed | MT |
07/05 | Transcript : Halozyme Therapeutics, Inc., Q1 2024 Earnings Call, May 07, 2024 |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+18.28% | 549.19Cr | |
+4.97% | 11TCr | |
+10.96% | 11TCr | |
-0.38% | 2.23TCr | |
-12.35% | 2.21TCr | |
-7.66% | 1.87TCr | |
-36.52% | 1.76TCr | |
-8.99% | 1.69TCr | |
+4.47% | 1.38TCr | |
+34.81% | 1.25TCr |
- Stock Market
- Equities
- HALO Stock
- News Halozyme Therapeutics, Inc.
- Halozyme Therapeutics Says Roche Gets European Commission's Approval for Tecentriq SC